Common analgesic use and chronic pain: Ramifications for neurodegenerative risks - A 13-year longitudinal study
Tracks
Federation Ballroom
Chronic Conditions
Dementia
Pain / Pain Management
Friday, November 15, 2024 |
11:30 AM - 11:45 AM |
Speaker
Dr Fatemeh Vazirian
Phd Student
University Of Tasmania
Common analgesic use and chronic pain: Ramifications for neurodegenerative risks - A 13-year longitudinal study
Abstract
Both chronic pain and analgesic use have been suggested to increase the risk of parkinsonism and dementia. We, therefore, investigated whether chronic pain, analgesic use alone, or their combination is associated with increased incident risk of these conditions.
Participants (n=355,709, mean age 56.51, 48.40% male) free of parkinsonism and dementia, reported their chronic musculoskeletal pain lasting ≥3 months and their use of common analgesics, including paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antidepressants. The incidence of all-cause parkinsonism, Parkinson's disease (PD), all-cause dementia, and Alzheimer's disease (AD) was recorded. Cox regression was used for the analyses.
Over a 13-year follow-up, 2,281 cases developed all-cause parkinsonism, 2,035 had PD, 4,778 developed all-cause dementia, and 2,052 had AD. In multivariable analyses, as compared to participants without chronic pain and analgesic use, chronic pain, analgesic use only and their combination had a higher risk of incident all-cause parkinsonism (Chronic pain only: hazard ratios (HRs) ranging from 1.13-1.21; Analgesic use only: 1.15-1.76; Combination: 1.21-2.13) and dementia (Chronic pain only: HRs 1.14-1.17; Analgesic use only: 1.18-1.92; Combination: 1.38-2.41) with individuals having the highest risk in those with both chronic pain and analgesic use. Similar patterns were observed for PD and AD risk.
While chronic pain, or analgesic use alone is associated with a higher risk of incident parkinsonism and dementia those with both had the highest risk. The mechanism for this warrants further investigation as it may inform approaches to reducing the risk of these conditions.
Participants (n=355,709, mean age 56.51, 48.40% male) free of parkinsonism and dementia, reported their chronic musculoskeletal pain lasting ≥3 months and their use of common analgesics, including paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and antidepressants. The incidence of all-cause parkinsonism, Parkinson's disease (PD), all-cause dementia, and Alzheimer's disease (AD) was recorded. Cox regression was used for the analyses.
Over a 13-year follow-up, 2,281 cases developed all-cause parkinsonism, 2,035 had PD, 4,778 developed all-cause dementia, and 2,052 had AD. In multivariable analyses, as compared to participants without chronic pain and analgesic use, chronic pain, analgesic use only and their combination had a higher risk of incident all-cause parkinsonism (Chronic pain only: hazard ratios (HRs) ranging from 1.13-1.21; Analgesic use only: 1.15-1.76; Combination: 1.21-2.13) and dementia (Chronic pain only: HRs 1.14-1.17; Analgesic use only: 1.18-1.92; Combination: 1.38-2.41) with individuals having the highest risk in those with both chronic pain and analgesic use. Similar patterns were observed for PD and AD risk.
While chronic pain, or analgesic use alone is associated with a higher risk of incident parkinsonism and dementia those with both had the highest risk. The mechanism for this warrants further investigation as it may inform approaches to reducing the risk of these conditions.
Biography
Dr. Fatemeh Vazirian.
PhD student at Menzies institution of University of Tasmania.
The PhD project is regarding the association between chronic musculoskeletal pain and neurodegenerative diseases.
Session Chair
Kaylee Rudd
Phd Student
University Of Tasmania